Routine peak anti-Xa monitoring in patients with renal insufficiency is not supported by evidence; adjusting LMWH doses based on pharmacokinetic changes without monitoring is sufficient.
Does peak anti-Xa monitoring improve clinical outcomes in patients with renal insufficiency receiving therapeutic doses of LMWH compared to pharmacokinetic dose reduction alone?
Routine peak anti-Xa monitoring is not supported by evidence for patients with renal insufficiency receiving appropriately dose-reduced LMWH; if monitoring is needed, trough concentrations are preferred.
INTRODUCTION: Several guidelines advise to monitor therapeutic LMWH therapy with peak anti-Xa concentrations in renal insufficiency with subsequent dose adjustments. A better understanding of the clinical association between peak anti-Xa concentrations and clinical outcomes is mandatory, because misunderstanding this association could lead to erroneous, and potentially even harmful, LMWH dose adjustments. AREAS COVERED: We reviewed the evidence of the widely applied therapeutic window for anti-Xa peak concentrations and report on the evidence for pharmacokinetic dose reduction in renal insufficiency, limitations of peak and trough anti-Xa concentration monitoring. EXPERT OPINION: The added value of peak anti-Xa monitoring in patients with renal insufficiency, receiving a dose reduced for pharmacokinetic changes, is not supported by data. Enoxaparin and nadroparin should be adjusted to 50-65% and 75-85% of the original dose for patients with a creatinine clearance (CrCL) of <30 ml/min and 30-60 ml/min, respectively. Tinzaparin should be adjusted to around 50% of the original dose for patients with a CrCL of <30 ml/min. In case anti-Xa monitoring is applied, trough concentration anti-Xa monitoring is preferred over peak monitoring, aiming at a maximum concentration of 0.4 IU/mL for once-daily dosed tinzaparin and 0.5 IU/mL for twice-daily dosed enoxaparin and nadroparin.
Broek et al. (Mon,) conducted a review in Renal insufficiency requiring low-molecular-weight heparin therapy. Anti-Xa monitoring and dose adjustment of low-molecular-weight heparin vs. Unmonitored LMWH with pharmacokinetic dose adjustment was evaluated. Routine peak anti-Xa monitoring in patients with renal insufficiency is not supported by evidence; adjusting LMWH doses based on pharmacokinetic changes without monitoring is sufficient.